Literature DB >> 9354685

Tumor necrosis factor alpha-induced eosinophil accumulation in rat skin is dependent on alpha4 integrin/vascular cell adhesion molecule-1 adhesion pathways.

M J Sanz1, A Hartnell, P Chisholm, C Williams, D Davies, V B Weg, M Feldmann, M A Bolanowski, R R Lobb, S Nourshargh.   

Abstract

Tumor necrosis factor alpha (TNFalpha) is a cytokine implicated in the pathogenesis of numerous chronic and acute inflammatory conditions. In the present study, we have characterized the ability of TNFalpha in inducing eosinophil accumulation in rat skin and have shown the inhibitory effects of anti-alpha4 integrin and anti-vascular cell adhesion molecule-1 (VCAM-1) antibodies on this response. The intradermal injection of recombinant human TNFalpha induced a slowly developing, dose-dependent accumulation of 111In-eosinophils in rat skin that was maximal at the dose of 10(-11) mol/site. Coadministration of TNFalpha with the soluble TNFalpha receptor (p55)-IgG fusion protein (TNFR-IgG) totally inhibited the 111In-eosinophil accumulation induced by the cytokine. The TNFalpha-induced 111In-eosinophil accumulation was not affected after pretreatment of rats with the platelet-activating factor (PAF) receptor antagonist UK-74,505 or the antihuman interleukin-8 monoclonal antibody (MoAb) DM/C7. In contrast, the intravenous administration of an anti-alpha4 integrin MoAb, HP2/1 (3.5 mg/kg), or an anti-VCAM-1 MoAb, 5F10 (2 mg/kg), greatly inhibited the 111In-eosinophil accumulation induced by TNFalpha (the responses detected at 10(-11) mol/site were inhibited by 78% and 50%, respectively). These results show that TNFalpha is an effective inducer of eosinophil accumulation in vivo, with this response being dependent on an interaction between alpha4 integrins and VCAM-1.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9354685

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Divergent mechanisms of action of the inflammatory cytokines interleukin 1-beta and tumour necrosis factor-alpha in mouse cremasteric venules.

Authors:  R E Young; R D Thompson; S Nourshargh
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  VCAM-1 contributes to rapid eosinophil accumulation induced by the chemoattractants PAF and LTB4: evidence for basal expression of functional VCAM-1 in rat skin.

Authors:  D Davies; K Larbi; A Allen; M Sanz; V B Weg; D O Haskard; R R Lobb; S Nourshargh
Journal:  Immunology       Date:  1999-05       Impact factor: 7.397

3.  Erythromycin exerts in vivo anti-inflammatory activity downregulating cell adhesion molecule expression.

Authors:  María-Jesús Sanz; Yafa Naim Abu Nabah; Miguel Cerdá-Nicolás; José-Enrique O'Connor; Andrew C Issekutz; Julio Cortijo; Esteban J Morcillo
Journal:  Br J Pharmacol       Date:  2005-01       Impact factor: 8.739

4.  Human eotaxin induces eosinophil extravasation through rat mesenteric venules: role of alpha4 integrins and vascular cell adhesion molecule-1.

Authors:  K Nagai; S Larkin; A Hartnell; K Larbi; M Razi Aghakhani; C Windley; D Davies; R R Lobb; T J Williams; S Nourshargh
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

5.  Rolipram inhibits leukocyte-endothelial cell interactions in vivo through P- and E-selectin downregulation.

Authors:  María-Jesús Sanz; Angeles Alvarez; Laura Piqueras; Miguel Cerdá; Andrew C Issekutz; Roy R Lobb; Julio Cortijo; Esteban J Morcillo
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

6.  Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism.

Authors:  A Salas; M Sans; A Soriano; J C Reverter; D C Anderson; J M Piqué; J Panés
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

7.  PKCζ as a promising therapeutic target for TNFα-induced inflammatory disorders in chronic cutaneous wounds.

Authors:  Jian Zhang; Xuekang Yang; Hongtao Wang; Bin Zhao; Xue Wu; Linlin Su; Songtao Xie; Yunchuan Wang; Jun Li; Jiaqi Liu; Mengdong Liu; Fu Han; Ting He; Wei Zhang; Ke Tao; Dahai Hu
Journal:  Int J Mol Med       Date:  2017-09-20       Impact factor: 4.101

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.